Cargando…

Drug resistance in leishmaniasis: Newer developments

Leishmaniasis is a vector borne protozoan disease and it remains a major public health problem world-wide. Lack of an effective vaccine and vector control program makes the chemotherapy as the primary tool for leishmaniasis. Antimonials were used as the first line of treatment for many years. Emerge...

Descripción completa

Detalles Bibliográficos
Autor principal: Mohapatra, Sarita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992802/
https://www.ncbi.nlm.nih.gov/pubmed/24754020
http://dx.doi.org/10.4103/2229-5070.129142
_version_ 1782312601174147072
author Mohapatra, Sarita
author_facet Mohapatra, Sarita
author_sort Mohapatra, Sarita
collection PubMed
description Leishmaniasis is a vector borne protozoan disease and it remains a major public health problem world-wide. Lack of an effective vaccine and vector control program makes the chemotherapy as the primary tool for leishmaniasis. Antimonials were used as the first line of treatment for many years. Emergence of resistance against this drug has become a major concern. Literatures and studies published on anti-leishmanial drug resistance, newer drug discovery for leishmanial resistance etc., in PubMed, Medline and Google search and reviewed thoroughly. Various newer drugs have been identified but, are in limited use because of high cost, toxicity, resistance etc., Recently, many newer mechanisms of drug resistance have been identified which may boost in future designing and development of drugs.
format Online
Article
Text
id pubmed-3992802
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39928022014-04-21 Drug resistance in leishmaniasis: Newer developments Mohapatra, Sarita Trop Parasitol Review Article Leishmaniasis is a vector borne protozoan disease and it remains a major public health problem world-wide. Lack of an effective vaccine and vector control program makes the chemotherapy as the primary tool for leishmaniasis. Antimonials were used as the first line of treatment for many years. Emergence of resistance against this drug has become a major concern. Literatures and studies published on anti-leishmanial drug resistance, newer drug discovery for leishmanial resistance etc., in PubMed, Medline and Google search and reviewed thoroughly. Various newer drugs have been identified but, are in limited use because of high cost, toxicity, resistance etc., Recently, many newer mechanisms of drug resistance have been identified which may boost in future designing and development of drugs. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC3992802/ /pubmed/24754020 http://dx.doi.org/10.4103/2229-5070.129142 Text en Copyright: © Tropical Parasitology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mohapatra, Sarita
Drug resistance in leishmaniasis: Newer developments
title Drug resistance in leishmaniasis: Newer developments
title_full Drug resistance in leishmaniasis: Newer developments
title_fullStr Drug resistance in leishmaniasis: Newer developments
title_full_unstemmed Drug resistance in leishmaniasis: Newer developments
title_short Drug resistance in leishmaniasis: Newer developments
title_sort drug resistance in leishmaniasis: newer developments
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992802/
https://www.ncbi.nlm.nih.gov/pubmed/24754020
http://dx.doi.org/10.4103/2229-5070.129142
work_keys_str_mv AT mohapatrasarita drugresistanceinleishmaniasisnewerdevelopments